REGENXBIO Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last twelve months. There are currently 2 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" REGENXBIO stock.
View analyst ratings for REGENXBIO or view top-rated stocks.

Wall Street analysts have given REGENXBIO a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but REGENXBIO wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

REGENXBIO is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for REGENXBIO.

REGENXBIO Inc. (NASDAQ:RGNX) announced its earnings results on Wednesday, May, 5th. The biotechnology company reported ($1.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.13) by $0.07. REGENXBIO had a negative trailing twelve-month return on equity of 27.80% and a negative net margin of 77.89%.
View REGENXBIO's earnings history.

REGENXBIO's stock was trading at $32.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RGNX stock has increased by 14.6% and is now trading at $37.68.
View which stocks have been most impacted by COVID-19.

8 analysts have issued twelve-month price objectives for REGENXBIO's stock. Their forecasts range from $37.00 to $95.00. On average, they expect REGENXBIO's share price to reach $62.50 in the next year. This suggests a possible upside of 65.9% from the stock's current price.
View analysts' price targets for REGENXBIO or view top-rated stocks among Wall Street analysts.

3 employees have rated REGENXBIO CEO Ken Mills on Glassdoor.com. Ken Mills has an approval rating of 68% among REGENXBIO's employees.

Some companies that are related to REGENXBIO include Vir Biotechnology (VIR), Halozyme Therapeutics (HALO), Beam Therapeutics (BEAM), Twist Bioscience (TWST), Adaptive Biotechnologies (ADPT), Recursion Pharmaceuticals (RXRX), Sana Biotechnology (SANA), Abcam (ABCM), SpringWorks Therapeutics (SWTX), Kodiak Sciences (KOD), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA), Relay Therapeutics (RLAY) and BioCryst Pharmaceuticals (BCRX).
View all of RGNX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Square (SQ).

REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."

REGENXBIO's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (14.83%), JPMorgan Chase & Co. (8.24%), Redmile Group LLC (5.51%), Point72 Asset Management L.P. (2.13%), Dimensional Fund Advisors LP (1.95%) and Geode Capital Management LLC (1.48%). Company insiders that own REGENXBIO stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Patrick J Christmas and Vittal Vasista.
View institutional ownership trends for REGENXBIO.

RGNX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., BNP Paribas Arbitrage SA, Botty Investors LLC, Man Group plc, State of New Jersey Common Pension Fund D, First Manhattan Co., Korea Investment CORP, and Credit Suisse AG. Company insiders that have sold REGENXBIO company stock in the last year include Curran Simpson, Kenneth T Mills, Patrick J Christmas, and Vittal Vasista.
View insider buying and selling activity for REGENXBIO or view top insider-selling stocks.

RGNX stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., BlackRock Inc., Point72 Asset Management L.P., Redmile Group LLC, Millennium Management LLC, Dimensional Fund Advisors LP, RTW Investments LP, and D. E. Shaw & Co. Inc..
View insider buying and selling activity for REGENXBIO or or view top insider-buying stocks.

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RGNX stock can currently be purchased for approximately $37.68.

REGENXBIO has a market capitalization of $1.60 billion and generates $154.57 million in revenue each year. The biotechnology company earns $-111,250,000.00 in net income (profit) each year or ($2.98) on an earnings per share basis.

REGENXBIO employs 306 workers across the globe.

The official website for REGENXBIO is www.regenxbio.com.

REGENXBIO is headquartered at 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850.

REGENXBIO's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at (240) 552-8181 or via email at [email protected]